A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Trial Profile

A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 May 2017

At a glance

  • Drugs SHP-659 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Parion Sciences
  • Most Recent Events

    • 01 May 2017 Results published in a Shire media release.
    • 03 May 2016 Results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2016 meeting, according to a Parion Sciences media release.
    • 30 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top